South America Lymphedema Treatment Market Share by Size and Growth 2028

The lymphedema treatment market in SAM is expected to grow from US$ 300.85 million in 2021 to US$ 419.04 million by 2028; it is estimated to grow at a CAGR of 4.8% from 2021 to 2028.

According to the Cleveland Clinic report, lymphedema can develop when there is damage to the lymphatic system or disruption in lymphatic damage. For example, lymph fluids drain into soft tissues, causing swelling and can occur anywhere in the body, with most cases occurring in arms and legs. Apart from that, cancer surgeries, radiation treatments, and other medical conditions raise the risk of lymphedema among patients. Additionally, among the gynecologic oncologic population, an increase in body mass index, insufficient levels of physical activity, and presence of pre-treatment lymphedema may be witnessed as potentially high-risk factors of lymphedema development. For example, oncological surgical procedures such as sentinel lymph nodes biopsy and radical dissection requiring excision of regional lymph nodes or vessels result in the development of secondary lymphedema. According to one report, lymphedema can occur after any cancer or its treatment affecting lymph node drainage. For example, it has been reported that it can occur within days and up to 30 years after the treatment for breast cancer. Also, 80% of patients experience onset within three years of surgery, and the remainder develops edema at a rate of 1% per year. Additionally, a large patient pool suffers from lower-limb lymphedema, particularly women after treatment for gynecological cancer, with the highest prevalence (36%) among vulvar cancer survivors and lowest prevalence (5%) among ovarian cancer survivors. Further, the overall incidence of arm lymphedema ranges from 8% to 56% at two years post-surgery. Furthermore, lymphedema may and do occur in the trunk, in addition to limbs. For example, radiation therapy to the chest wall is associated with the development of edema, particularly in the irradiated breast. Additionally, the healthcare system requires highly advanced treatment products. Therefore, major players are highly focusing on new and innovative product launches and approvals. Furthermore, with surging volume of lymphedema prevalence fuels the demand for lymphedema treatment ultimately contributing for the overall market growth.

The pandemic situation has subsequently resulted in the delay in spreading adequate awareness programs in the SAM region. The current global coronavirus disease 2019 (COVID-19) pandemic has not only resulted in millions of deaths but also posed indirect effects on other diseases and healthcare programs. In view of the current COVID-19 pandemic, and the need to maintain social distancing, government organizations issued the recommendation on 1st April 2020 to put all community-based surveys, active case-finding activities, and mass treatment campaigns for neglected tropical diseases on hold until further notice. However, as the cases of lymphedema treatment were rising in the region, government bodies bought the concept of telemedicine through which the awareness programs could reach the people suffering from lymphedema in Brazil and Argentina and help them in mitigating such risks. Another factor is that there are no proper treatments or cures for the concerned disease. The developing economies face risks as they could not address such risk factors posing threat to mankind. However, healthcare investments in Brazil and proper regulations are expected to positively impact the lymphedema treatment market in both Brazil and Argentina.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the lymphedema treatment market. The SAM lymphedema treatment market is expected to grow at a good CAGR during the forecast period.

SAM Lymphedema Treatment Market Revenue and Forecast to 2028 (US$ Million)

SAM Lymphedema Treatment Market Segmentation

SAM Lymphedema Treatment Market – By Condition Type

Primary Lymphedema
Secondary Lymphedema

SAM Lymphedema Treatment Market – By Treatment Type

Laser Therapy
Compression Devices
Drug Therapy
Physiological Procedures
- Lymphovenous Anastomosis (LVA)
- Vascularised Lymph Node Transfer (VLNT)
Debulking Procedures
- Surgical Debulking
- Liposuction
- Others
Others

SAM Lymphedema Treatment Market – By End-User

Hospitals
Clinics
Clinical Research Organizations
Others

SAM Lymphedema Treatment Market- By Country

Brazil
Argentina
Rest of SAM

SAM Lymphedema Treatment Market-Companies Mentioned

3M Company
BSN medical GmbH
Huntleigh Healthcare Limited
Lohmann & Rauscher GmbH & Co. KG
Mego Afek ltd
Sigvaris Group
Smith & Nephew

South America Lymphedema Treatment Market Strategic Insights

Get more information on this report

South America Lymphedema Treatment Market Segmentation Analysis

South America Lymphedema Treatment Market Report Highlights

South America Lymphedema Treatment Report Scope

Report Attribute	Details
Market size in 2021	US$ 300.85 Million
Market Size by 2028	US$ 419.04 Million
CAGR (2021 - 2028)	4.8%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Condition Type Primary Lymphedema and Secondary Lymphedema By Treatment Type Laser Therapy Compression Devices and Bandaging Drug Therapy Physiological Procedures Debulking Procedures Others By End User Hospitals Clinics Clinical Research Organizations
Regions and Countries Covered	South and Central America Brazil Argentina Rest of South and Central America
Market leaders and key company profiles	3M Company BSN medical GmbH Huntleigh Healthcare Limited Lohmann & Rauscher GmbH & Co. KG Mego Afek ltd Sigvaris Group Smith & Nephew